[HTML][HTML] Targeting cannabinoid receptors: current status and prospects of natural products
D An, S Peigneur, LA Hendrickx, J Tytgat - International journal of …, 2020 - mdpi.com
Cannabinoid receptors (CB1 and CB2), as part of the endocannabinoid system, play a
critical role in numerous human physiological and pathological conditions. Thus …
critical role in numerous human physiological and pathological conditions. Thus …
CB2 receptor in the CNS: From immune and neuronal modulation to behavior
W Grabon, S Rheims, J Smith, J Bodennec… - Neuroscience & …, 2023 - Elsevier
Despite low levels of cannabinoid receptor type 2 (CB2R) expression in the central nervous
system in human and rodents, a growing body of evidence shows CB2R involvement in …
system in human and rodents, a growing body of evidence shows CB2R involvement in …
Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3β pathway
H Wang, H Sui, Y Zheng, Y Jiang, Y Shi, J Liang… - Nanoscale, 2019 - pubs.rsc.org
Alzheimer's disease (AD) is the progressive development of fatal neurodegenerative
diseases. Owing to the unclearness of the pathogenesis of AD and the failure of the drug to …
diseases. Owing to the unclearness of the pathogenesis of AD and the failure of the drug to …
[HTML][HTML] Investigation of protective effects of apilarnil against lipopolysaccharide induced liver injury in rats via TLR 4/HMGB-1/NF-κB pathway
Sepsis caused by infection is one of the most important problems of clinical medicine. This
study aimed to determine the effect of Apilarnil (API), a bee product, on lipopolysaccharide …
study aimed to determine the effect of Apilarnil (API), a bee product, on lipopolysaccharide …
[HTML][HTML] Pharmacological properties, therapeutic potential and molecular mechanisms of JWH133, a CB2 receptor-selective agonist
The endocannabinoid system has attracted attention as a pharmacological target for several
pathological conditions. Cannabinoid (CB2)-selective agonists have been the focus of …
pathological conditions. Cannabinoid (CB2)-selective agonists have been the focus of …
Recent advances in the potential of cannabinoids for neuroprotection in Alzheimer's, Parkinson's, and Huntington's diseases
Three prevalent neurodegenerative diseases, Parkinson's, Alzheimer's, and Huntington's
are in need of symptomatic relief of slowing disease progression or both. This chapter …
are in need of symptomatic relief of slowing disease progression or both. This chapter …
[HTML][HTML] Endocannabinoid modulation in neurodegenerative diseases: In pursuit of certainty
Simple Summary Neurodegenerative diseases represent an important cause of morbidity
and mortality worldwide. Existing therapeutic options are limited and focus mostly on …
and mortality worldwide. Existing therapeutic options are limited and focus mostly on …
[HTML][HTML] Beyond pain relief: a review on Cannabidiol potential in medical therapies
M Luz-Veiga, J Azevedo-Silva, JC Fernandes - Pharmaceuticals, 2023 - mdpi.com
The phytocannabinoid cannabidiol (CBD) is receiving increasing attention due to its
pharmacological properties. Although CBD is extracted from Cannabis sativa, it lacks the …
pharmacological properties. Although CBD is extracted from Cannabis sativa, it lacks the …
[HTML][HTML] Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies
RS Duncan, SM Riordan, MC Gernon… - Neural Regeneration …, 2024 - journals.lww.com
Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a
variety of effects in the human body. They have been studied in cellular and animal models …
variety of effects in the human body. They have been studied in cellular and animal models …
Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?
KJ Thompson, AB Tobin - Cellular Signalling, 2020 - Elsevier
Alzheimer's disease (AD) is a neurodegenerative disorder which accounts for 60–70% of the
50 million worldwide cases of dementia and is characterised by cognitive impairments …
50 million worldwide cases of dementia and is characterised by cognitive impairments …